Clinical trial · Supplements / medicine · 14 Sept 2026
Obicetrapib slowed the rise of p-tau217 in a BROADWAY substudy, most in APOE4/E4
Source: Journal of Prevention of Alzheimer's Disease
What the research found
Study (prespecified biomarker substudy of a phase 3 CVD trial). Michael Davidson, Philip Scheltens and colleagues report in the Journal of Prevention of Alzheimer's Disease on 1,535 BROADWAY participants with APOE status and 12-month plasma p-tau217. Obicetrapib 10 mg attenuated p-tau217 rise versus placebo (adjusted mean 2.09% vs 4.94%; P=0.025). In APOE4/E4, p-tau217 fell 7.81% versus a 12.67% rise on placebo (20.48% difference; P=0.010). Biomarker shift, not a dementia diagnosis or prevention trial. Discussed on Peter Attia Drive #407 (14 September 2026) with Davidson; farmed from the primary paper. Prescription CETP inhibitor — clinician-only; not a supplement. Educational research notes, not medical advice.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
Read the original at Journal of Prevention of Alzheimer's Disease
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34